Business Context and Reporting Period
Company: DAXOR Corp.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2002
Business Overview: DAXOR operates laboratories providing semen and blood banking services and manufactures the BVA-100 Blood Volume Analyzer. The company is actively expanding its sales and marketing force to increase BVA-100 adoption, utilizing leasing and equipment loaner programs to facilitate hospital access.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2002 |
Six Months Ended June 30, 2001 |
|---|---|---|
| Total Revenues | $1,414,926 | $1,327,214 |
| Operating Revenues | $389,504 | $278,994 |
| Net Income | $110,665 | $134,224 |
| Net Income Per Share | $0.02 | $0.03 |
| Cash Flow from Operations | $73,315 | $144,555 |
| Total Assets | $43,506,322 | $43,540,153 |
| Total Liabilities | $8,030,387 | $8,211,186 |
| Shareholders' Equity | $35,475,935 | $35,328,967 |
| Marketable Securities (Fair Value) | $42,319,877 | $42,271,902 |
| Loans Payable | $730,318 | $1,000,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 6.6% year-over-year, driven by a 39.6% increase in operating revenues ($389,504 vs. $278,994). However, dividend income decreased slightly to $908,543 from $939,165.
- Profitability Decline: Net income decreased 17.6% to $110,665 from $134,224. This decline is attributed to a significant increase in Selling, General, and Administrative (SG&A) expenses, which rose 29.4% to $867,771 due to hiring additional sales and marketing personnel.
- Capital Gains: Gains on the sale of securities increased substantially to $95,064 from $9,731 in the prior period.
- Debt Reduction: The company repaid $300,000 of its bank loan, reducing total loans payable from $1,000,000 to $730,318.
- Cash Flow: Net cash provided by operating activities decreased 49.3% to $73,315, primarily due to the timing of working capital changes and lower net income.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management anticipates that sales of the BVA-100 Blood Volume Analyzer and associated kits will become the major source of income. The company is currently recruiting a National Sales and Marketing Director.
- Revenue Recognition Strategy: The company encourages leasing or renting BVA-100 equipment to hospitals. While this generates immediate kit sales, it results in slower recognition of operating income from equipment sales compared to direct purchases.
- Liquidity Position: The company holds significant marketable securities ($42.3 million) with a net unrealized gain of approximately $21 million. Current liabilities are heavily weighted by deferred taxes ($7.15 million) associated with these unrealized gains; excluding deferred taxes, current liabilities are approximately $876,240.
- Capital Allocation: Financial reserves are being used primarily to develop and market the Blood Volume Analyzer. The company is evaluating options for independent dealer distribution networks and blood volume instrumentation management programs.
- Risks: The "instrument loaner reagent plan" requires the use of company reserves and results in a slower return on capital expenditure. The company relies heavily on its investment portfolio for liquidity and income stability.
Investor Verification Checklist
- Investment Portfolio Valuation: Verify the fair value of the $42.3 million marketable securities portfolio and the sustainability of the $21 million unrealized gain.
- BVA-100 Adoption Rates: Confirm the progress of the new sales force and the actual uptake of leasing/rental programs for the Blood Volume Analyzer.
- Deferred Tax Liability: Assess the risk associated with the $7.15 million deferred tax liability, which would become payable if the investment portfolio were liquidated.
- Operating Margin Trends: Monitor whether the increased SG&A expenses yield proportional growth in operating revenues in future quarters.
- Debt Covenants: Review the terms of the $700,000 bank loan secured by marketable securities to ensure compliance with margin requirements.